News

Lucentis and Eylea patent expirations in the micro-crystal ball

By Keith Croes | January 14, 2020

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018…

OIS Index Posts a Strong Finish to 2019

By Michael Lachman | January 9, 2020

The OIS Index of ophthalmic stocks made a strong comeback in Q4-2019, following a rough Q3. The index gained 16.2% in Q4, slightly underperforming the…

Innovations a Highlight at Dry Eye Breakout Session

By Steve Lenier | January 8, 2020

The dry eye disease (DED) market is expected to have an annual compound growth rate of 4.5% between 2017 and 2025, which should help it…

BioGenware’s Speculet Seeks to Improve the Patient Experience

By Steve Lenier | December 18, 2019

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable,…

We’ve Got Your BAK

By Michelle Dalton | December 11, 2019

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would…

OIS Index Outperforms

By Michael Lachman | December 4, 2019

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and…

CorneaGen Aims to End Corneal Blindness

By Vanessa Caceres | December 4, 2019

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has…

RegenxBio sues FDA over clinical hold

By Keith Croes | November 27, 2019

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined…